| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.3 | 3e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.17 | 6e-05 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.22 | 0.0003 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0005 |